^
Association details:
| Biomarker: | PTEN mutation + TSC1 mutation |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies
Published date:
12/21/2023
Excerpt:
Disease control rate (PR+SD) was 63%. Of the responders in PR, 3/4pts had documented PTEN mutations (3/5 pts enrolled with PTEN mutations had PR); 2/4 of pts in PR had co-mutations (pt with leiomyosarcoma had both PTEN and TSC; pt with breast cancer had both PTEN and STK11); 1/4 pts in PR had AKT and mTOR mutation....The safety profile of mTORC1/2 inhibitor sapanisertib in combination with metformin was generally tolerable, with anti-tumor activity observed in patients with advanced malignancies harboring PTEN/ AKT/mTOR pathway alterations.
Secondary therapy:
metformin
DOI:
10.1158/2767-9764.CRC-22-0260
Source:
Title:
Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
Published date:
05/19/2021
Excerpt:
Pts with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without mTOR/AKT/PI3Kpathway alterations, received sapanisertib 3mg or 4mg daily together with metformin once to three times daily(500mg - 1500mg)....2/4 of pts in PR had co-mutations (pt with leiomyosarcoma had both PTENand TSC;pt with breast cancer had both PTENand STK11)...
Secondary therapy:
metformin
DOI:
10.1200/JCO.2021.39.15_suppl.3017
Trial ID:
